New Agents in Melanoma: Nivolumab, MK-3475, Pidilizumab
Dr. Atkins offers his perspective on the “race” between the top two anti-PD1 drugs (Merck’s MK-3475 and Bristol-Myers Squibb’s nivolumab), and weighs in on where a new agent, pidilizumab, fits into the picture.
Michael B. Atkins, MD, deputy director of the Georgetown-Lombardi Comprehensive Cancer Center, offers his perspective on the “race” between the top two anti-PD1 drugs (Merck’s MK-3475 and Bristol-Myers Squibb’s nivolumab) and insights as to which anti-PD1 agents are also showing the greatest promise in non-melanoma cancers. Dr. Atkins presented on phase II results of the new anti-PD1 drug pidilizumab at the 2014 ASCO Annual Meeting and weighs in on where this new agent fits into the picture.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
![A third of patients had a response [to lifileucel], and of the patients who have a response, half of them were alive at the 4-year follow-up.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F6b7c9a3270c71a70749ba86000cfc78a29d74309-2988x1702.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "A third of patients had a response [to lifileucel], and of the patients who have a response, half of them were alive at the 4-year follow-up.")
